Sam Altman's OpenAI's chatbot, ChatGPT, has become the talk of the town with its new feature providing Studio Ghibli-style artwork.

Search for the best digital art software and the best drawing software and you'll find plenty of options, all offering a broad array of brushes, design tools, and sharing possibilities to get your ...

And the best part? Eligible customers can sign up for a 30-day free trial and experience the incredible benefits Prime offers without paying a penny upfront. Prime aims to make your life more ...

After exploring every nook and cranny that Hulu has to offer in this generous 30-day trial, there are a wide range of subscription options to opt into, from $9.99 a month (with ads) all the way up ...

Correspondence brought up at trial also showed Marchick telling Woodall via email that she didn’t think she could help him. Marchick did eventually secure Woodall a job interview with a Disney ...

Seven members of the medical team that treated Diego Maradona before his death will today go on trial for homicide in Buenos Aires. The football legend died after suffering a heart attack at his ...

Stage 3 of Paris-Nice offers up a team time trial, as has become a traditional mid-week fixture in the French stage race. Tuesday's effort is 28.4km long across fairly rolling terrain between ...

Produced by ElevenLabs and News Over Audio (Noa) using AI narration. Listen to more stories on the Noa app. Khalil, a legal permanent resident of the United States and Palestinian activist who ...

Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest obesity drug from the manufacturer of blockbuster treatments Ozempic and Wegovy.

The 2025 edition of Tirreno-Adriatico kicks off today with a pan-flat 11.5km time trial in Lido di Camaiore to set the early GC positions and award the first blue leader’s jersey of the race.

LONDON/COPENHAGEN, March 10 (Reuters) - Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed ...